Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen

Amarnath Mukherjee, Thomas Darlington, Richard Baldwin, Charles Holz, Sage Olson, Prakash Kulkarni, Theodore L. Deweese, Robert H. Getzenberg, Robert Ivkov, Shawn E. Lupold

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The prostate-specific membrane antigen (PSMA) is an established target for the delivery of cancer therapeutic and imaging agents due to its high expression on the surface of prostate cancer cells and within the neovasculature of other solid tumors. Here, we describe the synthesis and screening of antibody-conjugated silica-coated iron oxide nanoparticles for PSMA-specific cell targeting. The humanized anti-PSMA antibody, HuJ591, was conjugated to a series of nanoparticles with varying densities of polyethylene glycol and primary amine groups. Customized assays utilizing iron spectral absorbance and enzyme-linked immunoassay (ELISA) were developed to screen microgram quantities of nanoparticle formulations for immunoreactivity and cell targeting ability. Antibody and PSMA-specific targeting of the optimized nanoparticle was evaluated using an isogenic PSMA-positive and PSMA-negative cell line pair. Specific nanoparticle targeting was confirmed by iron quantification with inductively coupled plasma mass spectrometry (ICP-MS). These methods and nanoparticles support the promise of targeted theranostic agents for future treatment of prostate and other cancers. Targeted MIONs: Silica-coated antibody-conjugated iron oxide nanoparticles were prepared, and their ability to specifically target prostate-specific membrane antigen (PSMA), a validated target in prostate cancer, was evaluated using iron spectral absorbance and enzyme-linked immunoassay (ELISA).

Original languageEnglish (US)
Pages (from-to)1356-1360
Number of pages5
JournalChemMedChem
Volume9
Issue number7
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Silicon Dioxide
Nanoparticles
Screening
Antibodies
Prostatic Neoplasms
Iron
Immunoenzyme Techniques
Cells
Inductively coupled plasma mass spectrometry
Enzymes
human glutamate carboxypeptidase II
ferric oxide
Amines
Tumors
Assays
Mass Spectrometry
Neoplasms
Imaging techniques
Cell Line
Therapeutics

Keywords

  • cancer
  • iron oxide
  • nanoparticles
  • prostate-specific membrane antigens
  • targeting

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen. / Mukherjee, Amarnath; Darlington, Thomas; Baldwin, Richard; Holz, Charles; Olson, Sage; Kulkarni, Prakash; Deweese, Theodore L.; Getzenberg, Robert H.; Ivkov, Robert; Lupold, Shawn E.

In: ChemMedChem, Vol. 9, No. 7, 2014, p. 1356-1360.

Research output: Contribution to journalArticle

Mukherjee, A, Darlington, T, Baldwin, R, Holz, C, Olson, S, Kulkarni, P, Deweese, TL, Getzenberg, RH, Ivkov, R & Lupold, SE 2014, 'Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen', ChemMedChem, vol. 9, no. 7, pp. 1356-1360. https://doi.org/10.1002/cmdc.201300549
Mukherjee, Amarnath ; Darlington, Thomas ; Baldwin, Richard ; Holz, Charles ; Olson, Sage ; Kulkarni, Prakash ; Deweese, Theodore L. ; Getzenberg, Robert H. ; Ivkov, Robert ; Lupold, Shawn E. / Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen. In: ChemMedChem. 2014 ; Vol. 9, No. 7. pp. 1356-1360.
@article{310138e5ce0144b38cf783afbc64af9c,
title = "Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen",
abstract = "The prostate-specific membrane antigen (PSMA) is an established target for the delivery of cancer therapeutic and imaging agents due to its high expression on the surface of prostate cancer cells and within the neovasculature of other solid tumors. Here, we describe the synthesis and screening of antibody-conjugated silica-coated iron oxide nanoparticles for PSMA-specific cell targeting. The humanized anti-PSMA antibody, HuJ591, was conjugated to a series of nanoparticles with varying densities of polyethylene glycol and primary amine groups. Customized assays utilizing iron spectral absorbance and enzyme-linked immunoassay (ELISA) were developed to screen microgram quantities of nanoparticle formulations for immunoreactivity and cell targeting ability. Antibody and PSMA-specific targeting of the optimized nanoparticle was evaluated using an isogenic PSMA-positive and PSMA-negative cell line pair. Specific nanoparticle targeting was confirmed by iron quantification with inductively coupled plasma mass spectrometry (ICP-MS). These methods and nanoparticles support the promise of targeted theranostic agents for future treatment of prostate and other cancers. Targeted MIONs: Silica-coated antibody-conjugated iron oxide nanoparticles were prepared, and their ability to specifically target prostate-specific membrane antigen (PSMA), a validated target in prostate cancer, was evaluated using iron spectral absorbance and enzyme-linked immunoassay (ELISA).",
keywords = "cancer, iron oxide, nanoparticles, prostate-specific membrane antigens, targeting",
author = "Amarnath Mukherjee and Thomas Darlington and Richard Baldwin and Charles Holz and Sage Olson and Prakash Kulkarni and Deweese, {Theodore L.} and Getzenberg, {Robert H.} and Robert Ivkov and Lupold, {Shawn E.}",
year = "2014",
doi = "10.1002/cmdc.201300549",
language = "English (US)",
volume = "9",
pages = "1356--1360",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen

AU - Mukherjee, Amarnath

AU - Darlington, Thomas

AU - Baldwin, Richard

AU - Holz, Charles

AU - Olson, Sage

AU - Kulkarni, Prakash

AU - Deweese, Theodore L.

AU - Getzenberg, Robert H.

AU - Ivkov, Robert

AU - Lupold, Shawn E.

PY - 2014

Y1 - 2014

N2 - The prostate-specific membrane antigen (PSMA) is an established target for the delivery of cancer therapeutic and imaging agents due to its high expression on the surface of prostate cancer cells and within the neovasculature of other solid tumors. Here, we describe the synthesis and screening of antibody-conjugated silica-coated iron oxide nanoparticles for PSMA-specific cell targeting. The humanized anti-PSMA antibody, HuJ591, was conjugated to a series of nanoparticles with varying densities of polyethylene glycol and primary amine groups. Customized assays utilizing iron spectral absorbance and enzyme-linked immunoassay (ELISA) were developed to screen microgram quantities of nanoparticle formulations for immunoreactivity and cell targeting ability. Antibody and PSMA-specific targeting of the optimized nanoparticle was evaluated using an isogenic PSMA-positive and PSMA-negative cell line pair. Specific nanoparticle targeting was confirmed by iron quantification with inductively coupled plasma mass spectrometry (ICP-MS). These methods and nanoparticles support the promise of targeted theranostic agents for future treatment of prostate and other cancers. Targeted MIONs: Silica-coated antibody-conjugated iron oxide nanoparticles were prepared, and their ability to specifically target prostate-specific membrane antigen (PSMA), a validated target in prostate cancer, was evaluated using iron spectral absorbance and enzyme-linked immunoassay (ELISA).

AB - The prostate-specific membrane antigen (PSMA) is an established target for the delivery of cancer therapeutic and imaging agents due to its high expression on the surface of prostate cancer cells and within the neovasculature of other solid tumors. Here, we describe the synthesis and screening of antibody-conjugated silica-coated iron oxide nanoparticles for PSMA-specific cell targeting. The humanized anti-PSMA antibody, HuJ591, was conjugated to a series of nanoparticles with varying densities of polyethylene glycol and primary amine groups. Customized assays utilizing iron spectral absorbance and enzyme-linked immunoassay (ELISA) were developed to screen microgram quantities of nanoparticle formulations for immunoreactivity and cell targeting ability. Antibody and PSMA-specific targeting of the optimized nanoparticle was evaluated using an isogenic PSMA-positive and PSMA-negative cell line pair. Specific nanoparticle targeting was confirmed by iron quantification with inductively coupled plasma mass spectrometry (ICP-MS). These methods and nanoparticles support the promise of targeted theranostic agents for future treatment of prostate and other cancers. Targeted MIONs: Silica-coated antibody-conjugated iron oxide nanoparticles were prepared, and their ability to specifically target prostate-specific membrane antigen (PSMA), a validated target in prostate cancer, was evaluated using iron spectral absorbance and enzyme-linked immunoassay (ELISA).

KW - cancer

KW - iron oxide

KW - nanoparticles

KW - prostate-specific membrane antigens

KW - targeting

UR - http://www.scopus.com/inward/record.url?scp=84903818774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903818774&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201300549

DO - 10.1002/cmdc.201300549

M3 - Article

VL - 9

SP - 1356

EP - 1360

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 7

ER -